EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access

A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer

Satoru Nihei, Haruki Ujiie, Kazuki Saito, Tatsuki Ikeda, Junichi Asaka, Mizunori Yaegashi, Koichi Asahi, Kenzo Kudo

In Vivo · 2026-01 · 40 (1) · 465-473

DOI: 10.21873/invivo.14210 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift In Vivo, online erschienen am 02.01.2026. Verfasst von Satoru Nihei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Iwate Medical University Hospital, Iwate, Japan; satoru@iwate-med.ac.jp. Hauptthemen laut MEDLINE: Amlodipine, Proteinuria, Colorectal Neoplasms, Hypertension. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Bevacizumab (Bev) often induces hypertension and proteinuria. Optimal antihypertensive management in this setting remains unclear, and studies comparing angiotensin II receptor blockers (ARBs) and calcium channel blockers (CCBs) are limited. The objective of this study was to compare the effects of the ARB azilsartan and the CCB amlodipine on hypertension and proteinuria. PATIENTS AND METHODS: Patients with demonstrated systolic/diastolic blood pressure (SBP/DBP) ≥140/90 mmHg during Bev therapy for colorectal cancer were randomly assigned 1:1 to either the azilsartan group or the amlodipine group and were followed up for 18 weeks. The primary outcome was urinary protein-to-creatinine ratio (UPCR). Secondary outcomes included BP changes and achievement of target BP (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmlodipineProteinuriaColorectal NeoplasmsHypertensionBenzimidazolesBevacizumabOxadiazolesHumansMaleFemaleMiddle AgedAgedBlood PressureAntihypertensive AgentsProspective StudiesTreatment OutcomeCalcium Channel Blockers

Stichwörter der Autor:innen

Bevacizumabamlodipineazilsartancalcium channel blockerhypertensionproteinuriarenin-angiotensin system inhibitor

Substanzen

AmlodipineBenzimidazolesazilsartanBevacizumabOxadiazolesAntihypertensive AgentsCalcium Channel Blockers

Autor:innen und Institutionen

  • Department of Pharmacy, Iwate Medical University Hospital, Iwate, Japan; satoru@iwate-med.ac.jp.
  • Division of Clinical Pharmaceutics and Pharmacy Practice, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University, Iwate, Japan.
  • Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University, Iwate, Japan.
  • Department of Pharmacy, Iwate Medical University Hospital, Iwate, Japan.
  • Department of Surgery, School of Medicine, Iwate Medical University, Iwate, Japan.
  • Division of Nephrology and Hypertension, Department of Internal Medicine, School of Medicine, Iwate Medical University, Iwate, Japan.

Zitieren

APA

Nihei, S., Ujiie, H., Saito, K., Ikeda, T., Asaka, J., Yaegashi, M., Asahi, K., & Kudo, K. (2026). A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer. In Vivo, 40(1), 465-473. https://doi.org/10.21873/invivo.14210

Vancouver

Nihei S, Ujiie H, Saito K, Ikeda T, Asaka J, Yaegashi M, et al. A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer. In Vivo. 2026;40(1):465-473. doi:10.21873/invivo.14210

BibTeX
@article{Nihei2026,
  author = {Nihei, Satoru and Ujiie, Haruki and Saito, Kazuki and Ikeda, Tatsuki and Asaka, Junichi and Yaegashi, Mizunori and Asahi, Koichi and Kudo, Kenzo},
  title = {A Prospective Comparison of Azilsartan and Amlodipine for Bevacizumab-induced Hypertension and Proteinuria in Colorectal Cancer},
  journal = {In Vivo},
  year = {2026},
  volume = {40},
  number = {1},
  pages = {465--473},
  doi = {10.21873/invivo.14210}
}
Kostenlos starten →